Evidence map›Paper›PMID 38762640›Full record

ArticleAnnals of surgical oncology2024

Neoadjuvant Chemotherapy Does Not Improve Survival in cT2N0M0 Gastric Adenocarcinoma Patients: A Multicenter Propensity Score Analysis.

Francesco Abboretti, Céline Lambert, Markus Schäfer, Bruno Pereira, Bertrand Le Roy, Diane Mège, Guillaume Piessen, Johan Gagnière, Caroline Gronnier, Styliani Mantziari and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Francesco AbborettiDepartment of Visceral Surgery, Lausanne University Hospital, CHUV, Lausanne, Switzerland.
Céline LambertBiostatistics Unit, DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Markus SchäferDepartment of Visceral Surgery, Lausanne University Hospital, CHUV, Lausanne, Switzerland.
Bruno PereiraBiostatistics Unit, DRCI, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Bertrand Le RoyDepartment of Digestive and Oncologic Surgery, Hospital Nord, CHU de Saint-Etienne, Saint-Priest-en-Jarez, France.
Diane MègeDepartment of Digestive Surgery, Aix Marseille Univ, APHM, Timone University Hospital, Marseille, France.
Guillaume PiessenDepartment of Digestive and Oncological Surgery, CHU Lille, Lille, France.
Johan GagnièreDepartment of Digestive Surgery and Liver Transplantation, Estaing University Hospital, Clermont-Ferrand, France.
Caroline Gronnier *Eso-Gastric Surgery Unit, Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital, Pessac, France.
Styliani Mantziari *Department of Visceral Surgery, Lausanne University Hospital, CHUV, Lausanne, Switzerland. styliani.mantziari@chuv.ch.ORCID http://orcid.org/0000-0003-1315-1898
ADENOKGAST Study Group
AFC-French Association of Surgery

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccording to current international guidelines, stage cT2N0M0 gastric adenocarcinoma warrants preoperative chemotherapy followed by surgery. However, upfront surgery is often preferred in clinical practice, depending on patient clinical status and local treatment preferences.

objectiveThe aim of the present study was to assess the impact of neoadjuvant chemotherapy in overall survival (OS) and disease-free survival (DFS) of cT2N0M0 patients.

methodsA retrospective analysis was performed among 32 centers, including gastric adenocarcinoma patients operated between January 2007 and December 2017. Patients with cT2N0M0 stage were divided into upfront surgery (S) and neoadjuvant chemotherapy followed by surgery (CS) groups. Inverse probability of treatment weighting (IPTW) was used to compensate for baseline differences between the groups.

resultsAmong the 202 patients diagnosed with cT2N0M0 stage, 68 (33.7%) were in the CS group and 134 (66.3%) were in the S group. CS patients were younger (mean age 62.7 ± 12.8 vs. 69.8 ± 12.1 years for S patients; p < 0.001) and had a better health status (World Health Organization performance status = 0 in 60.3% of CS patients vs. 34.5% of S patients; p = 0.006). During follow-up, recurrence occurred in 27.2% and 19.6% of CS and S patients, respectively, after IPTW (p = 0.32). Five-year OS was similar between CS and S patients (78.9% vs. 68.3%; p = 0.42), as was 5-year DFS (70.4% vs. 68.5%; p = 0.96). Neoadjuvant chemotherapy was associated with neither OS nor DFS in multivariable analysis after IPTW.

conclusionsPatients with cT2N0M0 gastric adenocarcinoma did not present a survival or recurrence benefit if treated with perioperative chemotherapy followed by surgery as opposed to surgery alone.

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyPropensity ScoreStomach NeoplasmsAgedChemotherapy, AdjuvantFemaleFollow-Up StudiesGastrectomyHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesNeoadjuvant therapyPropensity scoreStomach neoplasmsSurvival analysis

Identifiers

PMID38762640
PMCPMC11236876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.